Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)
Today, Cantor Fitzgerald reiterated its Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) with a price target of $16.00.
Some recent analyst ratings include
- 3/16/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 2/13/2018-Evercore ISI initiated coverage with a Outperform rating.
- 1/25/2018-Roth Capital Reiterated Rating of Buy .
- 1/24/2018-HC Wainwright Reiterated Rating of Buy .
- 11/28/2017-Leerink Swann Reiterated Rating of Buy.
- 10/27/2017-Piper Jaffray Companies Reiterated Rating of Buy.
Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 61.36%.
- On 7/19/2018 Kurt Von Emster, Director, bought 153,846 with an average share price of $6.50 per share and the total transaction amounting to $999,999.00.
- On 3/5/2018 Kurt Von Emster, Director, sold 13,353 with an average share price of $15.51 per share and the total transaction amounting to $207,105.03.
- On 2/14/2018 Kurt Von Emster, Director, sold 218,057 with an average share price of $15.89 per share and the total transaction amounting to $3,464,925.73.
- On 2/7/2018 Kurt Von Emster, Director, sold 40,763 with an average share price of $12.35 per share and the total transaction amounting to $503,423.05.
- On 2/5/2018 Kurt Von Emster, Director, sold 18,831 with an average share price of $12.14 per share and the total transaction amounting to $228,608.34.
- On 2/2/2018 Kurt Von Emster, Director, sold 90,098 with an average share price of $12.15 per share and the total transaction amounting to $1,094,690.70.
- On 1/31/2018 Kurt Von Emster, Director, sold 97,639 with an average share price of $12.22 per share and the total transaction amounting to $1,193,148.58.
Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 14.04 up +1.55 12.41% with shares trading hands.
